Myeloproliferative Neoplasms

First-line venetoclax plus azacitidine did not improve overall survival vs placebo plus azacitidine in treatment-naive, higher-risk MDS.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

Rusfertide earned an FDA breakthrough designation for polycythemia vera based on findings from the phase 3 VERIFY study.

Marina Kremyanskaya, MD, PhD, discusses the investigation of divesiran in polycythemia vera.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Marina Kremyanskaya, MD, PhD, discusses early-phase findings with divesiran in patients with polycythemia vera.

Naseema Gangat, MBBS, delves into the role of ruxolitinib as a standard of care for the treatment of patients with polycythemia vera and myelofibrosis.

Naseema Gangat, MBBS, discusses the potential use of ruxolitinib and ropeginterferon alfa-2b-njft to reduce JAK2 allele burden in polycythemia vera.

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Johannes Schetelig, MD, discusses challenges with assessing haploidentical related vs mismatched unrelated donor transplantation in high-risk AML/ALL/MDS

The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.

Andrew Kuykendall, MD, outlines the limitations of current clinical end points and discusses the need for molecularly informed drug development in MPN.

Marina Kremyanskaya, MD, PhD, discusses safety and early efficacy findings with divesiran in polycythemia vera.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

Nuvisertib has received orphan drug designation from the EMA for patients with myelofibrosis.

Francesca Palandri, MD, PhD, discusses findings from a post hoc analysis of momelotinib-induced hemoglobin level improvements in myelofibrosis with anemia.

John Mascarenhas, MD, discusses early findings from the IMproveMF trial combining imetelstat with ruxolitinib in intermediate- to high-risk myelofibrosis.

Francesca Palandri, MD, PhD, discusses the results from a subgroup analysis of momelotinib vs ruxolitinib in myelofibrosis with anemia and low platelet counts.

Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.

John Mascarenhas, MD, discusses the rationale for evaluating imetelstat in patients with relapsed/refractory myelofibrosis.

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations in MDS and AML.

Hetty E. Carraway, MD, MBA, highlights the evolving molecular classification of MDS and novel agents in the therapeutic arsenal.

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.

Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.